Skip to main content

Table 4 Most frequent reasons for drop out across global regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Study program

Treatment group

North America

Western Europe

Australia/South Africa

Japan

Asia

Eastern Europe/Russia

South America/Mexico

IDENTITY

Placebo

1. AEs = 43 (48%)

1. AEs = 19 (51%)

1. CG decision = 4 (44%)

1. AEs = 4 (36%)

1. Participant decision = 9 (45%)

1. Participant decision = 32 (59%)

1. Participant decision = 6 (38%)

2. Participant decision = 15 (17%)

2. Participant decision = 9 (24%)

1. Participant decision = 4 (44%)

2. CG decision = 3 (27%)

2. AEs = 6 (30%)

2. AEs = 15 (28%)

2. CG decision = 3 (19%)

2. Death = 3 (27%)

2. AEs = 3 (19%)

Semagacestat 140 mg PO

1. AEs = 105 (55%)

1. AEs = 55 (66%)

1. AEs = 12 (48%)

1. AEs = 28 (74%)

1. AEs = 18 (47%)

1. AEs = 33 (46%)

1. AEs = 25 (49%)

2. Participant decision = 38 (20%)

2. Participant decision = 12 (14%)

2. Death = 5 (20%)

2. CG decision = 6 (16%)

2. Participant decision = 13 (34%)

2. Participant decision = 12 (42%)

2. Participant decision = 13 (25%)

EXPEDITION

Placebo

1. AEs = 39 (31%)

1. AEs = 19 (38%)

1. AEs = 3 (50%)

1. AEs = 5 (50%)

1. Participant decision = 4 (36%)

1. Participant decision = 9 (38%)

1. Participant decision = 10 (36%)

2. CG decision = 33 (26%)

2. Participant decision = 14 (28%)

2. CG decision = 1 (17%)

2. Participant decision = 2 (20%)

2. AEs = 2 (18%)

2. AEs = 5 (21%)

2. AEs = 7 (25%)

2. Physician decision = 1 (17%)

2. Death = 2 (18%)

2. Death = 1 (17%)

Solanezumab 400 mg IV

1. CG decision = 39 (27%)

1. AEs = 16 (38%)

1. AEs = 7 (64%)

1. AEs = 5 (45%)

1. AEs = 2 (25%)

1. CG decision = 6 (43%)

1. Participant decision = 6 (29%)

2. AEs = 34 (24%)

2. Participant decision = 10 (24%)

2. Participant decision = 2 (18%)

2. CG decision = 4 (36%)

1. Participant decision = 2 (25%)

2. AEs = 3 (21%)

2. AEs = 5 (24%)

2. Physician decision = 2 (18%)

1. Protocol violation = 2 (25%)

2. Participant decision = 3 (21%)

  1. aData are presented as count (%). AE = Adverse event; CG = Caregiver; IV = Intravenously; PO = By mouth.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193